Intravenous Immunoglobulin Versus Anti-D Immunoglobulin: When Better Treatment May Not Be the Best Treatment

In this volume of The Journal, Lioger et al report on a systematic review comparing the efficacy and safety of anti-D immunoglobulin (anti-D) and intravenous immunoglobulin (IVIG) in the treatment of pediatric immune thrombocytopenia (ITP).1 The methodology of the authors is meticulous, and this work clearly highlights the significant gaps in evidence that persist in the management of ITP despite the fact that it is one of the most common diseases encountered in pediatric hematology. The authors performed a search for randomized controlled trials that enrolled children <18 years of age with primary ITP and that evaluated the effect of anti-D and IVIG.

https://ift.tt/2zDzVzN